The Importance of IGHV Mutational Status in del(11q) and del(17p) Chronic Lymphocytic Leukemia

Dohner, 2000, Genomic aberrations and survival in chronic lymphocytic leukemia, N Engl J Med, 343, 1910, 10.1056/NEJM200012283432602 Tam, 2009, De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the M. D. Anderson and Mayo Clinic experience, Blood, 114, 957, 10.1182/blood-2009-03-210591 Tomomatsu, 2010, Chronic lymphocytic leukemia in a Japanese population: varied immunophenotypic profile, distinctive usage of frequently mutated IGH gene, and indolent clinical behavior, Leuk Lymphoma, 51, 2230, 10.3109/10428194.2010.527403 Best, 2009, A subset of Binet stage A CLL patients with TP53 abnormalities and mutated IGHV genes have stable disease, Leukemia, 23, 212, 10.1038/leu.2008.260 Gladstone, 2011, Importance of immunoglobulin heavy chain variable region mutational status in del(13q) chronic lymphocytic leukemia, Leuk Lymphoma, 52, 1873, 10.3109/10428194.2011.585529 Damle, 1999, Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia, Blood, 94, 1840, 10.1182/blood.V94.6.1840 Hamblin, 1999, Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia, Blood, 94, 1848, 10.1182/blood.V94.6.1848 Hamblin, 2002, CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease, Blood, 99, 1023, 10.1182/blood.V99.3.1023 Kharfan-Dabaja, 2008, Clinical and therapeutic implications of the mutational status of IgVH in patients with chronic lymphocytic leukemia, Cancer, 113, 897, 10.1002/cncr.23671 Trojani, 2010, ZAP-70, IgVh, and cytogenetics for assessing prognosis in chronic lymphocytic leukemia, Cancer Biomark, 6, 1, 10.3233/CBM-2009-0114 Catovsky, 2007, Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 trial): a randomised controlled trial, Lancet, 370, 230, 10.1016/S0140-6736(07)61125-8 Dreger, 2010, Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial, Blood, 116, 2438, 10.1182/blood-2010-03-275420 Schetelig, 2008, Allogeneic hematopoietic stem-cell transplantation for chronic lymphocytic leukemia with 17p deletion: a retrospective European Group for Blood and Marrow Transplantation analysis, J Clin Oncol, 26, 5094, 10.1200/JCO.2008.16.2982